A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.

Chen, Xuanrong; Shen, Haishan; Shao, Yi; Ma, Qianwang; Niu, Yuanjie; Shang, Zhiqun

Chen, Xuanrong; Shen, Haishan; Shao, Yi; Ma, Qianwang; Niu, Yuanjie; Shang, Zhiqun.

Afiliación

Chen X; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Shen H; Urology Development, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Shao Y; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Ma Q; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Niu Y; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Shang Z; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.

Transl Androl Urol ; 10(2): 954-962, 2021 Feb.

Article en En | MEDLINE | ID: mdl-33718095

Palabras clave

Proteolytic targeting chimera; prostate cancer (PCa); transcription factor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Transl Androl Urol Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google